PERSONALIZED TEST FOR TREATMENT PREDICTION IN DEPRESSION

October 6, 2016

Major Depressive Disorder is one of the most common psychiatric disorders in the US, with over 15 million people impacted and costing $100 billion annually, of which less than half achieve symptom remission with the first medication tried. The cost associated with a prolonged duration of depressive symptoms is substantial, including lower employment levels and higher risk for a range of other general medical conditions.

Spotlight

PCI Synthesis

A Leading Supplier to Life Sciences Companies and Users of Advanced Materials PCI Synthesis is a custom chemical manufacturer of new chemical entities (NCEs), generic APIs, and other specialty chemical products. PCI Synthesis operates two sites in the Greater Boston area.

OTHER WHITEPAPERS
news image

Assessing drug target association from biological evidences

whitePaper | July 7, 2022

The full drug target profile identification is many times a necessary step in drug development process. Recently, the move to a more holistic approach in drug discovery has resulted in the increasing use of cell-based assays to discover new biologically active small molecules.

Read More
news image

New Active Substances Launched During 2021

whitePaper | June 27, 2022

Following on from our review of trends in the current pharmaceutical R&D pipeline this supplement takes a look at the industry’s success stories of 2021

Read More
news image

MOLECULAR GLUES LANDSCAPE IN DRUG DISCOVERY

whitePaper | June 21, 2022

nduced-proximity targeted protein degradation (TPD) is a ground-breaking strategy in drug discovery that has emerged during the last decade.

Read More
news image

The convergence of the pharmaceutical and medicaldevices industries

whitePaper | May 26, 2022

The medical device and pharmaceutical industries each share in a mission to improve health outcomes, from prevention to intervention. As a result of this shared mission, integration and overlap between these two industries has been taking place for decades.

Read More
news image

Pharma R&D Annual Review

whitePaper | March 15, 2022

Successes in 2021 – New active substance drug launches

Read More
news image

Pharma R&D Annual Review 2022

whitePaper | May 5, 2022

welcome to pharmaprojects'2022 review of trends in pharmaceutical R&D for 30 year now, I've been taking an anual look at the evloution of pharma

Read More

Spotlight

PCI Synthesis

A Leading Supplier to Life Sciences Companies and Users of Advanced Materials PCI Synthesis is a custom chemical manufacturer of new chemical entities (NCEs), generic APIs, and other specialty chemical products. PCI Synthesis operates two sites in the Greater Boston area.

Events